Ronald Buijsen is this year’s recipient of the Gewirtz Award for postdoctoral researchers and Young Industrial Professionals of the Oligonucleotide Therapeutics Society (OTS). He received the award for his contributions […]
On Monday 3 October, the kick-off of our CureQ consortium was held: an introduction of all those involved who will work together over the next 5 years on predicting, delaying […]
The first participant of the SCA7 study reported yesterday at our Radboudumc Expertise Center for Rare and Hereditary Movement Disorders. With this, we have officially started the research into the […]
Ronald Buijsen is this year’s recipient of the Gewirtz Award for postdoctoral researchers and Young Industrial Professionals of the Oligonucleotide Therapeutics Society (OTS). He received the award for his contributions […]
On Monday 3 October, the kick-off of our CureQ consortium was held: an introduction of all those involved who will work together over the next 5 years on predicting, delaying […]
The first participant of the SCA7 study reported yesterday at our Radboudumc Expertise Center for Rare and Hereditary Movement Disorders. With this, we have officially started the research into the […]
